Mendiratta et al. have developed an AR signature for prostate cancer that is based on the
expression of 300 genes. The AR signature is decreased with androgen deprivation therapy …

Androgen receptor (AR) is a member of the steroid hormone receptor family of molecules.
AR primarily is responsible for mediating the physiologic effects of androgens by binding to …

Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been
treated by hormonal therapy. Almost all prostate cancer patients initially respond to …

The androgen receptor (AR) is the principal target for treatment of non–organ-confined
prostate cancer (PCa). Androgen deprivation therapies (ADT) directed against the AR ligand …

Purpose: The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized
in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the …

2 Background: Significant genomic diversity exists in the androgen receptor (AR) and its
activity (AR-A) in mCRPC. In localized prostate cancer, the biologic, prognostic, and …

Simple Summary Approximately 1 in 8 men will be diagnosed with prostate cancer (PCa) at
some point in their lifetime. Five-year survival rate for patients with local or regionally spread …

The androgen receptor gene (AR) plays an important role in molecular signaling and
regulation and the subsequent cellular growth of prostate cancer. In addition, it is a highly …

Mutations in the androgen receptor (AR) have been detected in experimental and clinical
prostate tumors. Mice with enforced prostate‐specific expression of one such receptor …

Purpose Despite treatments which lower circulating androgens, advanced prostate cancers
often maintain androgen receptor (AR) signaling. The variable response to secondary …